Complementary and alternative therapies for Crohn’s disease, like acupuncture and meditation, are useful approaches to managing symptoms in combination with a treatment plan.

The FDA approval of Selarsdi 130 mg/26 ml in a single-dose vial for intravenous infusion expands the label to include ...

Eli Lilly and Johnson & Johnson are seeking label expansions for Omvoh and Tremfya, respectively, in Crohn’s disease ...

It was how it would affect him socially.Being in his early 20s at the time, Kefford was focused on socialising and dating, ...

Results provide a mechanistic explanation of why early loss of p53 signaling is frequently observed in UC-associated ...

Monte Rosa Therapeutics, Inc. secures $150M partnership with Novartis for immune treatments. Click for my updated look at ...

Crohn’s disease is a type of inflammatory bowel disease (IBD) that involves periods of remission and flares. Symptoms can ...

Eli Lilly announced that mirikizumab achieved long-term remission in Phase 3 IBD studies, showing promise for ulcerative ...

Johnson & Johnson's Tremfya shows promising results in Phase 3 GRAVITI study for Crohn's disease, achieving significant clinical remission and endoscopic response at 48 weeks.

ALTB-268 demonstrated its anti-inflammatory effect in an acute colitis hPSGL-1 mouse model.The data confirmed that ALTB-268 acts as an immune ...

(RTTNews) - Johnson & Johnson (JNJ) Monday announced positive results from Phase 3 GRAVITI study of Tremfya as both induction and maintenance therapy in Crohn's disease, a type of inflammatory bowel ...